Company
Haima Therapeutics
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for the treatment of bleeding and a variety of blood-related diseases.
Also known as Haima Therapeutics, LLC
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Cleveland, OH, United States
- Legal name
- Haima Therapeutics, LLC
Record updated 28 September 2026
About
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for the treatment of bleeding and a variety of blood-related diseases. Haima’s initial focus is on platelet-inspired therapies to mitigate active bleeding and bleeding risks after traumatic injury, surgery, thrombocytopenia, and rare bleeding disorders. Haima’s lead technology, called SynthoPlate, is a novel, fully-synthetic hemostatic agent that mitigates bleeding by acting at the site of injury and amplifying your body’s natural clotting mechanisms.
Funding snapshot
- Total raised
- $8.9MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Grant, $4M2025-09-15
Funding rounds
- Grant
- $4M2025-09-15, Company stated
- Grant
- $1.9M2025-07-15, Company stated
- Grant
- $3M2020-09-30, Company stated
Products
- Other
- SynthoPlate